TrialBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2023

Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.

Justin Stebbing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.